Is antiplatelet therapy safe after intracerebral hemorrhage?
Michael D Hill
Correspondence Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Room 1242A, Foothills Medical Centre, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada
Email michael.hill@calgaryhealthregion.ca
This article has no abstract so we have provided the first paragraph of the full text.
The prescription of antiplatelet agents to patients with previous ICH appears contradictory; however, many patients with hemorrhage have comorbid atherosclerotic disease. For ICH survivors, there is little evidence on how to balance the risks in practice.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
